Reslizumab Dosage

Medically reviewed by Drugs.com. Last updated on Mar 8, 2024.

Usual Adult Dose for Asthma

3 mg/kg IV over 20 to 50 minutes every 4 weeks

Comments:

• Do not administer as an IV push or bolus.
• The infusion should be discontinued immediately if the patient experiences a severe systemic reaction, including anaphylaxis.

Use: For the add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:

• Anaphylaxis occurred in 0.3% of patients in studies.
• Observe patients for an appropriate period of time after the infusion and healthcare professionals should be prepared to manage anaphylaxis that can be life-threatening.
• Discontinue therapy immediately if the patient experiences anaphylaxis.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug is for IV use only. Do not administer as an IV push or bolus.
• This drug should be administered in a healthcare setting by a healthcare professional prepared to manage anaphylaxis.
• If refrigerated prior to administration, allow the diluted solution to reach room temperature before use.
• Use an infusion set with an in-line, low protein-binding filter (pore size of 0.2 micron). This drug is compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters.
• The infusion time may vary depending on the total volume to be infused as based upon patient weight.
• Do not infuse this drug concomitantly in the same IV line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of this drug with other agents.
• Observe the patient over the infusion and for an appropriate period of time following infusion.

Storage requirements:

• Refrigerate unreconstituted product at 2C to 8 (36F to 46F). Do not freeze. Do not shake. Protect the vials from light by storing in the original package until time of use.
• If not used immediately, store diluted solutions in the refrigerator at 2C to 8C (36F to 46F) or at room temperature up to 25C (77F), protected from light, for up to 16 hours. The time between preparation and administration should not exceed 16 hours.

Reconstitution/preparation techniques:

• Remove from the refrigerator. To minimize foaming, do not shake.
• Visually inspect for particulate matter and discoloration prior to administration. The solution should be clear to slightly hazy/opalescent, colorless to slightly yellow. Since this drug is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates. Do not administer if discolored or if other foreign particulate matter is present.
• Withdraw the proper volume based on weight-based dosage.
• Discard any unused portion.
• Dispense syringe contents slowly into an infusion bag containing 50 mL of 0.9% sodium chloride injection; to minimize foaming. This drug is compatible with polyvinylchloride (PVC) or polyolefin infusion bags. Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.

General:

• This drug is indicated for treatment of asthma of the eosinophilic phenotype but not for other eosinophilic conditions.
• This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer